Altitude Sickness Prevention and Efficacy of Comparative Treatments

Trial ID or NCT#

NCT02604173

Status

not recruiting iconNOT RECRUITING

Purpose

This study is designed to be the first to examine the novel drug budesonide for prevention of acute mountain sickness in comparison to acetazolamide and in the context of rapid ascent to high altitude. The investigators will accomplish these objectives with a prospective, double blinded view of a large population of hikers who are ascending at their own rate in a true hiking environment.

Official Title

A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. 1. Male and Female 2. Sea level-dwelling hikers 3. Between ages 18-65
Exclusion Criteria:
  1. 1. History of allergy to acetazolamide or budesonide (or other corticosteroids) 2. Taken NSAIDs, acetazolamide, or corticosteroids in the one week prior to study enrollment. 3. Hazardous medical conditions which precludes the ability to moderately hike to high altitude including: sickle cell anemia, asthma, or COPD, severe anemia, or severe coronary arterial disease. 4. Pregnancy or suspected pregnancy. 5. Participants who are younger than 18 years of age and more than 65 6. Sleep above 4'000 elevation in the preceding 1 week. 7. History of asthma or COPD 8. Current symptoms of an acute upper respiratory illness. 9. Unable to complete a moderately strenuous hike at high altitude.

Contact us to find out if this trial is right for you.

Contact

Grant S Lipman, MD
415-290-9286